ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012

NCI May Support More Training Of Cancer Surgeons

May 23, 1975

Goodfellow To Lead Gynecologic Oncology Research Team At Ohio State University

January 11, 2013

IOM Report Urges Providers To Address Psychological Needs Of Cancer Patients.

November 23, 2007

Drug Company Cries Foul Over Clams Of Taxotere’s Superiority To Taxol

June 11, 1993

NCI To Merge Two Intramural Divisions To Form Center For Cancer Research.

January 12, 2001